Stock Market Reviews

Read and share opinions on HOTH (Hoth Therapeutics, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

Latest News

• Hoth Therapeutics Launches VA-Backed Study of Novel GDNF Weight Loss Therapy Targeting Obesity and Fatty Liver Disease
  Oct 27, 2025
• Hoth Therapeutics Reports FDA Orphan Drug Designation and Strong Preclinical Data for HT-KIT in Rare c-KIT-Driven Cancers
  Oct 21, 2025
• Hoth Therapeutics Expands Artificial Intelligence Initiative, Selects NVIDIA AI Enterprise Platform
  Oct 8, 2025
• Hoth Therapeutics CEO Robb Knie to Present at BIO-Europe in Vienna, Austria November 3-5, 2025
  Oct 7, 2025
• Hoth Therapeutics Expands HT-001 Development with Patent Filings Targeting Drug-Induced Hypersensitivity, Radiotherapy-Induced Rash, and MENIN Inhibitor-Associated Skin Toxicities
  Sep 24, 2025
• Hoth Therapeutics, Inc. (HOTH) Files EMA Application for Global Expansion of HT-001 Skin Therapy
  Sep 23, 2025
• Hoth Therapeutics Issues Shareholder Update: HT-001, HT-KIT, Expanded Treasury Reserve Strategy, and VA Obesity Program Drive Strongest Position in Company History
  Sep 16, 2025
• Hoth Therapeutics Secures Key European Regulatory Milestone with EMA Submission for Phase II Trial of HT-001 in Cancer Patients Suffering from EGFRi-Induced Skin Toxicities
  Sep 10, 2025
• Hoth Therapeutics Taps Lantern Pharma's PredictBBB.ai Platform -- Breakthrough AI With 94% Accuracy Driving Next-Gen Drug Development
  Sep 4, 2025
• Hoth Therapeutics' Cancer Therapeutic HT-KIT Surpasses Preclinical Milestones With Potent Anti-Tumor Activity and GLP-Validated Bioanalytical Results, Exceeding Regulatory Standards
  Sep 2, 2025
• EXCLUSIVE: Hoth Therapeutics' Antisense Therapy Demonstrates Efficacy Against KIT-Driven Cancers
  Sep 2, 2025
• Hoth Therapeutics Announces Engagement with ICON and Expansion of Phase II Clinical Trial for HT-001 in Europe
  Jul 29, 2025
• Hoth Therapeutics Signs VA Research Deal to Advance GDNF as Breakthrough Therapy for Obesity and Fatty Liver - Side-by-Side Study vs. Semaglutide Begins
  Jul 22, 2025
• Hoth Therapeutics says HT-001 met primary endpoint in CLEER-001 study
  Jun 25, 2025
• Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market
  Jun 25, 2025
• Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty liver disease.
  Jun 25, 2025